1. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  2. EGFR

EGFR

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, heparin binding EGF-like growth factor, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras–mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3_ kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C–protein kinase C (PLC-PKC) pathways.

EGFR Related Products (85):

Cat. No. Product Name Effect Purity
  • HY-15772
    AZD-9291 Inhibitor 99.95%
    AZD-9291 is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively.
  • HY-50895
    Gefitinib Inhibitor 99.95%
    Gefitinib is an inhibitor that specifically binds and inhibits the EGFR tyrosine kinase, with the IC50 value of 2-37 nM in NR6wtEGFR cells.
  • HY-50898
    Lapatinib Inhibitor 99.90%
    Lapatinib is a potent EGFR and ErbB2 inhibitor with IC50 of 10.2 and 9.8 nM, respectively.
  • HY-50896
    Erlotinib Inhibitor 99.82%
    Erlotinib inhibits purified EGFR kinase with an IC50 of 2 nM.
  • HY-10261
    Afatinib Inhibitor 99.58%
    Afatinib is an irreversible, dual EGFR/HER2 inhibitor, shows potent activity against wild-type and mutant forms of EGFR and HER2, with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.
  • HY-P9905
    Cetuximab Inhibitor 99.70%
    Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with antitumor activity.
  • HY-104065
    Pyrotinib Inhibitor 98.40%
    Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively.
  • HY-19816A
    Avitinib maleate Inhibitor >98.0%
    Avitinib maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (EGFR) inhibitor with an IC50 of 7.68 nM.
  • HY-12000
    AG-490 Inhibitor 98.86%
    AG-490 is an tyrosine kinase inhibitor, inhibits EGFR and Stat-3.
  • HY-12008
    Erlotinib Hydrochloride Inhibitor 99.91%
    Erlotinib hydrochloride inhibits purified EGFR kinase with an IC50 of 2 nM.
  • HY-14596
    Genistein Inhibitor 99.64%
    Genistein is a potent inhibitor of the protein tyrosine kinase (PTK) activity of the EGFR in vitro with an IC50 of 0.7 μg/mL (0.6 μM).
  • HY-32721
    Neratinib Inhibitor 99.54%
    Neratinib is an orally available, irreversible tyrosine kinase inhibitor with IC50s of 59 nM and 92 nM for HER2 and EGFR, respectively.
  • HY-15772A
    AZD-9291 mesylate Inhibitor 99.95%
    AZD-9291 mesylate is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively.
  • HY-13524
    AG-1478 Inhibitor 99.83%
    AG-1478 is a selective EGFR tyrosine kinase inhibitor with IC50 of 3 nM.
  • HY-19730
    Olmutinib Inhibitor 99.95%
    Olmutinib (HM61713; BI-1482694) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with IC50 values of 9.2 nM and 10 nM in HCC827 and H1975 cell, respectively.
  • HY-13272
    Dacomitinib Inhibitor 99.91%
    Dacomitinib is a specific and irreversible inhibitor of the ERBB family of kinases with IC50 of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.
  • HY-10261A
    Afatinib dimaleate Inhibitor 99.81%
    Afatinib dimaleate is an irreversible, dual EGFR/HER2 inhibitor, shows potent activity against wild-type and mutant forms of EGFR and HER2, with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.
  • HY-12872
    EGF816 Inhibitor 99.85%
    EGF816 is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min−1 on EGFR(L858R/790M) mutant, respectively.
  • HY-16069
    Irbinitinib Inhibitor 99.57%
    Irbinitinib (ARRY-380; ONT-380) is a potent and selective HER2 inhibitor with an IC50 of 8 nM.
  • HY-18750
    AZD3759 Inhibitor 99.61%
    AZD3759 is a potent, oral active, central nervous system-penetrant, EGFR inhibitor.